Research Radartracking 85 published studies · 25 human · 14 clinical trials · 14 cancer pages · updated Jun 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “small cell carcinoma”.
1 of 85 studies
ReviewInconclusiveLimited evidenceTier 4 · clinical

Detailed overview on rare malignant ovarian tumors

Bulletin du cancer · Mar 2020 · narrative review

germ cell tumorssex cord-stromal ovarian tumorssmall cell carcinomamalignant Brenner tumorsmucinous carcinomaclear cell carcinomalow-grade serous carcinomaovarian carcinosarcoma

This is a narrative review summarizing pathology, clinical presentation, and treatment recommendations for a selection of rare malignant ovarian tumors. The authors state these tumors are heterogeneous, comprise about 10% of ovarian tumors, and that data and treatment recommendations are limited; they note that staging follows FIGO but treatment differs for germ cell and sex cord-stromal tumors. The review is based on recent national guidelines and related important publications.

Reported effect: Proportion of ovarian tumors 10%

Key findings
  • Rare malignant ovarian tumors covered include germ cell tumors, sex cord-stromal ovarian tumors, small cell carcinoma, malignant Brenner tumors, and rare epithelial tumors such as mucinous, clear cell and low-grade serous carcinomas, as well as ovarian carcinosarcoma.
  • Together these rare malignant ovarian tumors comprise about 10% of all ovarian tumors.
  • Because of low prevalence and heterogeneity, data and treatment recommendations for these tumors are limited.
  • Although all ovarian tumors are staged according to FIGO staging of epithelial ovarian tumors, treatment differs especially for germ cell tumors and sex cord-stromal ovarian tumors.
  • Non-epithelial ovarian tumors can arise from a variety of ovarian precursor cells such as germ cells, granulosa cells, theca cells, or stromal fibroblasts, reflecting divergent origins.
  • The article provides a comprehensive summary of pathology, clinical presentation, and therapy recommendations for a selection of rare ovarian tumors based on the latest national guidelines and important publications.
Limitations: Narrative review: methodology for literature selection is not specified in the abstract (not necessarily systematic).; No primary new data are reported in this article (summary of existing literature and guidelines).; Conclusions are limited by the low prevalence and substantial heterogeneity of the tumors discussed.; Therapeutic recommendations are constrained by limited evidence available for these rare tumor types..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed